Recent Updates
Recently added Catalysts
CNSY Positive Sentiment

Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives

Thursday, August 13, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Cerenome, through its subsidiary CNSide Diagnostics, has secured an in-network agreement with Health Care Service Corporation. This agreement marks a significant milestone, achieving the company's goal for commercial payer coverage by 2026. As a result, CNSide's coverage will now extend to over 150 million lives, enhancing access to its services.
Price reaction · baseline $3.7 (2026-08-12 close) · hit pre-market · 1 other CNSY headline(s) in the window, move may be shared
day 0 close
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • Cerenome achieved its full-year 2026 commercial payer coverage objective.
  • The agreement expands CNSide's contracted coverage significantly.
  • Over 150 million covered lives will now have access to CNSide.

Full Press Release Details

Agreement marks achievement of Cerenome’s full-year 2026 commercial payer coverage objective for CNSide HOUSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), announced today that it has signed

Frequently Asked Questions

What is the significance of Cerenome's new agreement?

The agreement expands CNSide's coverage to over 150 million lives.

What is CNSide?

CNSide is a diagnostic service offered by Cerenome's subsidiary.

When does Cerenome aim to achieve full coverage?

Cerenome aims to achieve its coverage objective by the end of 2026.

Who is Health Care Service Corporation?

Health Care Service Corporation is a major health insurance provider.

ShareAdd on Google
Tags: CNSY Viatris Investor Conferences Healthcare Cerenome CNSide Health Care Service Corporation commercial payer coverage
Last updated: Aug 13, 2026

Biotech snapshot

Cash runway
$9M liquidity · $3M/mo burn
~3 mo
High dilution risk